These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16846101)

  • 1. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism.
    Mousain-Bosc M; Roche M; Polge A; Pradal-Prat D; Rapin J; Bali JP
    Magnes Res; 2006 Mar; 19(1):53-62. PubMed ID: 16846101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. I. Attention deficit hyperactivity disorders.
    Mousain-Bosc M; Roche M; Polge A; Pradal-Prat D; Rapin J; Bali JP
    Magnes Res; 2006 Mar; 19(1):46-52. PubMed ID: 16846100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnesium VitB6 intake reduces central nervous system hyperexcitability in children.
    Mousain-Bosc M; Roche M; Rapin J; Bali JP
    J Am Coll Nutr; 2004 Oct; 23(5):545S-548S. PubMed ID: 15466962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined vitamin B6-magnesium treatment in autism spectrum disorder.
    Nye C; Brice A
    Cochrane Database Syst Rev; 2005 Oct; 2005(4):CD003497. PubMed ID: 16235322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B vitamin supplementation reduces excretion of urinary dicarboxylic acids in autistic children.
    Kałużna-Czaplińska J; Socha E; Rynkowski J
    Nutr Res; 2011 Jul; 31(7):497-502. PubMed ID: 21840465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined vitamin B6-magnesium treatment in autism spectrum disorder.
    Nye C; Brice A
    Cochrane Database Syst Rev; 2002; (4):CD003497. PubMed ID: 12519599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological treatments in patients with pervasive developmental disorders: A review].
    Béhérec L; Quilici G; Rosier A; Gerardin P; Campion D; Guillin O
    Encephale; 2014 Apr; 40(2):188-96. PubMed ID: 24369879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
    Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children.
    Lelord G; Callaway E; Muh JP
    Acta Vitaminol Enzymol; 1982; 4(1-2):27-44. PubMed ID: 7124567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism.
    Martineau J; Barthelemy C; Garreau B; Lelord G
    Biol Psychiatry; 1985 May; 20(5):467-78. PubMed ID: 3886023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormally high plasma levels of vitamin B6 in children with autism not taking supplements compared to controls not taking supplements.
    Adams JB; George F; Audhya T
    J Altern Complement Med; 2006; 12(1):59-63. PubMed ID: 16494569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specifying PDD-NOS: a comparison of PDD-NOS, Asperger syndrome, and autism.
    Walker DR; Thompson A; Zwaigenbaum L; Goldberg J; Bryson SE; Mahoney WJ; Strawbridge CP; Szatmari P
    J Am Acad Child Adolesc Psychiatry; 2004 Feb; 43(2):172-80. PubMed ID: 14726723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The presentation of anxiety in children with pervasive developmental disorders.
    Weisbrot DM; Gadow KD; DeVincent CJ; Pomeroy J
    J Child Adolesc Psychopharmacol; 2005 Jun; 15(3):477-96. PubMed ID: 16092912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability and validity of the Pervasive Developmental Disorders Assessment System.
    Kurita H; Koyama T; Inoue K
    Psychiatry Clin Neurosci; 2008 Apr; 62(2):226-33. PubMed ID: 18412847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of nutritional supplements for reducing symptoms in autism-spectrum disorder: a case report.
    Xia RR
    J Altern Complement Med; 2011 Mar; 17(3):271-4. PubMed ID: 21417812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of MAGNE-B6 on the clinical and biochemical manifestations of the syndrome of attention deficit and hyperactivity in children].
    Nogovitsina OR; Levitina EV
    Eksp Klin Farmakol; 2006; 69(1):74-7. PubMed ID: 16579066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of porcine secretin in children with autism and pervasive developmental disorder.
    Kern JK; Van Miller S; Evans PA; Trivedi MH
    J Autism Dev Disord; 2002 Jun; 32(3):153-60. PubMed ID: 12108616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study.
    Di Martino A; Melis G; Cianchetti C; Zuddas A
    J Child Adolesc Psychopharmacol; 2004; 14(2):207-18. PubMed ID: 15319018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Review of psychopharmacological treatments in adolescents and adults with autistic disorders].
    Baghdadli A; Gonnier V; Aussilloux C
    Encephale; 2002; 28(3 Pt 1):248-54. PubMed ID: 12091786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin B6-magnesium treatment for autism: the current status of the research.
    Murza KA; Pavelko SL; Malani MD; Nye C
    Magnes Res; 2010 Jun; 23(2):115-7. PubMed ID: 20562088
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.